Resistance Mechanisms to AZD9291 and Rociletinib-Response

Reinhard Büttner¹, Jürgen Wolf², Roman K Thomas³, Martin L Sos^{4

5

6}

Affiliations

¹ Institute of Pathology, University Hospital Cologne, Cologne, Germany.
² Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
³ Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
⁴ Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. msos1@uni-koeln.de.
⁵ Molecular Pathology, Institute of Pathology, University Hospital Cologne, Cologne, Germany.
⁶ Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

Comment

Reinhard Büttner et al. Clin Cancer Res. 2017.

. 2017 Jul 15;23(14):3967-3968.

doi: 10.1158/1078-0432.CCR-17-0948.

Reinhard Büttner¹, Jürgen Wolf², Roman K Thomas³, Martin L Sos^{4

5

6}

¹ Institute of Pathology, University Hospital Cologne, Cologne, Germany.
² Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany.
³ Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
⁴ Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany. msos1@uni-koeln.de.
⁵ Molecular Pathology, Institute of Pathology, University Hospital Cologne, Cologne, Germany.
⁶ Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

No abstract available

Comment on

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Ortiz-Cuaran S, et al. Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252416
Resistance Mechanisms to AZD9291 and Rociletinib-Letter.
Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E. Van Der Steen N, et al. Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. Clin Cancer Res. 2017. PMID: 28710317 No abstract available.